Zacks Research Upgrades Rezolute (NASDAQ:RZLT) to "Hold"

Rezolute logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded Rezolute from “strong sell” to “hold.” Other analysts are more bullish: 12 rate the stock Buy, and the consensus is “Moderate Buy” with an average price target of $11.67.
  • Rezolute reported a quarterly loss of $0.18 per share, slightly better than analysts’ estimate of a $0.19 loss.
  • The stock opened at $4.20; its 52-week range is $1.07 to $11.16.
  • MarketBeat previews the top five stocks to own by December 1st.

Rezolute (NASDAQ:RZLT - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report issued on Wednesday, Zacks reports.

RZLT has been the topic of a number of other research reports. Citizens Jmp raised their price objective on Rezolute from $11.00 to $15.00 and gave the company a "market outperform" rating in a research report on Tuesday, October 6th. Craig Hallum upgraded Rezolute from a "hold" rating to a "buy" rating and lifted their target price for the company from $4.00 to $7.00 in a research note on Tuesday, September 29th. Lake Street Capital boosted their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, October 6th. HC Wainwright increased their price target on shares of Rezolute from $5.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, September 25th. Finally, Cantor Fitzgerald upgraded shares of Rezolute from a "neutral" rating to an "overweight" rating in a report on Monday, October 5th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.67.

View Our Latest Report on RZLT

Rezolute Price Performance

NASDAQ RZLT opened at $4.20 on Wednesday. The company's 50-day simple moving average is $4.05 and its two-hundred day simple moving average is $3.94. Rezolute has a one year low of $1.07 and a one year high of $11.16.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Analysts predict that Rezolute will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Rezolute

Several hedge funds have recently made changes to their positions in the company. Auxano Advisors LLC acquired a new stake in shares of Rezolute during the second quarter worth about $52,000. Sequoia Financial Advisors LLC purchased a new stake in Rezolute in the second quarter valued at approximately $75,000. WINTON GROUP Ltd acquired a new position in Rezolute in the 2nd quarter worth approximately $88,000. Integrated Wealth Concepts LLC acquired a new position in Rezolute in the 2nd quarter worth approximately $143,000. Finally, Hsbc Holdings PLC raised its position in Rezolute by 189.4% during the 1st quarter. Hsbc Holdings PLC now owns 36,939 shares of the company's stock worth $113,000 after buying an additional 24,177 shares during the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

About Rezolute

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company's lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rezolute Right Now?

Before you consider Rezolute, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.

While Rezolute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines